Today: 2 July 2026
Browse Category

NASDAQ:PLTR 29 December 2025 - 20 January 2026

AI stocks head into MLK Day break mixed: Nvidia and Intel slip as AMD, Broadcom firm

AI stocks head into MLK Day break mixed: Nvidia and Intel slip as AMD, Broadcom firm

New York, January 18, 2026, 12:33 EST — The market has closed. U.S. chip and software stocks tied to AI closed Friday on a mixed note ahead of the long holiday weekend. Advanced Micro Devices and Broadcom posted gains, with AMD up 1.7% at $231.83 and Broadcom climbing 2.6% to $351.71. Meanwhile, Nvidia slipped 0.5% to $186.23, and Intel dropped 2.8% to $46.96. On the software side, Palantir slid 3.4%, Alphabet dipped 0.9%, and Microsoft edged up 0.7%.
18 January 2026
·········
AI stocks today: Nvidia counters China chip-payment report, Palantir gets Citi boost, Alphabet rides Siri deal

AI stocks today: Nvidia counters China chip-payment report, Palantir gets Citi boost, Alphabet rides Siri deal

NEW YORK, Jan 13, 2026, 06:41 — Premarket AI shares showed a mixed picture in early trading Tuesday as Nvidia clarified its payment terms for the H200 AI chips. The company said Chinese buyers aren’t required to pay upfront and emphasized it won’t charge for products not delivered. Nvidia edged up 0.03% to $184.94.
13 January 2026
····
Palantir (PLTR) faces fresh valuation test as investor says “too early to call” despite Truist’s $223 target

Palantir (PLTR) faces fresh valuation test as investor says “too early to call” despite Truist’s $223 target

Palantir Technologies’ rally is hitting a familiar snag: the stock price. Billy Duberstein, a “five-star” investor, said it’s “too early to call” whether the recent slump—shares have dropped about 14% since the November third-quarter report—signals a cooling off. He described the valuation as “frothy” but noted, “The seemingly insane valuation might not be as crazy as it seems if Palantir can continue to deliver the blockbuster growth it did in 2025.” Duberstein added, “Only time will tell if the AI revolution can continue propelling Palantir to new heights, or if the company’s growth will inevitably stall out.” The timing is crucial as investors aim to separate genuine winners from hype heading into 2026, with Palantir now serving as a litmus test for how much the market will value fast-growing AI-related software. The stock’s recent swings have raised the stakes—when expectations run this high, even minor shortfalls can appear significant.
11 January 2026
·
Palantir Stock Forecast 2026: New $186 Target Signals Modest Upside as Analysts Raise EPS View

Palantir Stock Forecast 2026: New $186 Target Signals Modest Upside as Analysts Raise EPS View

Wall Street’s average 12-month price target for Palantir Technologies has risen to $186 from $153 over the past 90 days, with estimates ranging from $50 to $255, LSEG data showed on Thursday. The stock closed at $177.75 on Dec. 31, about 14% below its 52-week high of $207.52, and analysts now see 2026 earnings per share — profit divided by shares outstanding — at $1.009 on average, up 18.8% in 90 days. Palantir ended 2025 with a market value of about $449.6 billion and traded at 193.1 times forward earnings — a valuation based on expected profit — while the average broker recommendation stayed at “Hold” ahead of the company’s expected Feb. 2 report, the data showed. app.stockreportsplus.com+1 The updated forecast matters at the start of 2026 because Palantir has become a bellwether for AI-linked software shares. When valuation is stretched, even small changes in estimates can move a stock sharply.
2 January 2026
··
1 2 3 4 5 6 … 9

Stock Market Today

  • Cramer Sees Moderna's Pipeline Opening Up Beyond Covid
    July 1, 2026, 7:50 PM EDT. CNBC's Jim Cramer said on Mad Money that Moderna now looks different than during the Covid rush, with a cancer pipeline and vaccines reaching outside infectious diseases. He sees many programs still years out but calls for buying pullbacks, pointing to Moderna's track to profits and new data from late-stage cancer trials-like the melanoma combo trial with Merck's Keytruda. Moderna shares have jumped almost 150% this year but still trade under pandemic highs. Cramer also mentions fresh regulatory wins, including FDA advisory backing for its flu shot and a European nod for its combined Covid-flu vaccine.
Go toTop